解读卵巢癌患者欧洲癌症研究与治疗组织生活质量问卷核心30量表评分的最小重要差异
本研究基于四项已发表的EORTC试验数据,为卵巢癌患者EORTC QLQ-C30各量表估计组内变化和组间差异的最小重要差异(MID)。采用均值变化法和线性回归法,以临床锚定和分布法为辅,确定了14个量表中7个恶化、11个改善的锚定MID,多数量表绝对值在4至10分之间。
要点
- 卵巢癌患者EORTC QLQ-C30组内变化MID:改善4至19分,恶化-9至-4分。
- 组间差异MID:改善3至13分,恶化-11至-4分,多数量表绝对值4至10分。
- 14个量表中7个确定恶化MID,11个确定改善MID,可辅助未来试验样本量估算。
核心结论
- 本研究结果有助于解读卵巢癌患者EORTC QLQ-C30评分,并为未来以该量表为终点的卵巢癌试验提供样本量计算依据。
研究设计与样本
- 数据来源于四项已发表的EORTC试验,采用均值变化法和线性回归法分别估计组内变化和组间差异的MID,并以分布法MID作为支持证据。
主要发现
- 锚定MID在14个EORTC QLQ-C30量表中确定了7个恶化维度和11个改善维度。
- 组内变化锚定MID:改善为4至19分,恶化为-9至-4分。
- 组间差异MID:改善为3至13分,恶化为-11至-4分。
- 多数量表锚定MID绝对值范围为4至10分。
关键数值与推荐
- 组内变化锚定MID:改善4至19分,恶化-9至-4分。
- 组间差异锚定MID:改善3至13分,恶化-11至-4分。
- 多数量表锚定MID绝对值范围为4至10分。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Minimal important differences (MIDs) are useful for interpreting changes or differences in health-related quality of life scores in terms of clinical importance. There are currently no MID guidelines for the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire core 30 (EORTC QLQ-C30) specific to ovarian cancer. This study aims to estimate MIDs for interpreting group-level change of EORTC QLQ-C30 scores in ovarian cancer. METHODS: Data were derived from four EORTC published trials. Clinical anchors for each EORTC QLQ-C30 scale were selected using correlation strength and clinical plausibility. MIDs for within-group change and between-group differences in change over time were estimated via mean change method and linear regression respectively. For each EORTC QLQ-C30 scale, MID estimates from multiple anchors were summarized via weighted-correlation. Distribution-based MIDs were also examined as supportive evidence. RESULTS: Anchor-based MIDs were determined for deterioration in 7 of the 14 EORTC QLQ-C30 scales assessed, and in 11 scales for improvement. Anchor-based MIDs for within-group change ranged from 4 to 19 (improvement) and - 9 to -4 (deterioration). Between-group MIDs ranged from 3 to 13 (improvement) and - 11 to -4 (deterioration). Generally, absolute anchor-based MIDs for most scales ranged from 4 to 10 points. CONCLUSIONS: Our findings will aid interpretation of EORTC QLQ-C30 scores in ovarian cancer and inform sample size calculations in future ovarian cancer trials with endpoints that are based on EORTC QLQ-C30 scales.
引用
- Musoro JZ, Coens C, Greimel E, et al. Minimally important differences for interpreting European Organisation for Research and Treatment of Cancer (EORTC) Quality of life Questionnaire core 30 scores in patients with ovarian cancer. Gynecol Oncol. 2020. PMID: 32972782. doi:10.1016/j.ygyno.2020.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。